Free Trial

BriaCell Therapeutics (BCTX) Stock Price, News & Analysis

BriaCell Therapeutics logo
$0.79
-0.02 (-2.46%)
(As of 11/1/2024 ET)

About BriaCell Therapeutics Stock (NASDAQ:BCTX)

Key Stats

Today's Range
$0.78
$0.83
50-Day Range
$0.47
$1.24
52-Week Range
$0.46
$5.97
Volume
332,317 shs
Average Volume
1.63 million shs
Market Capitalization
$28.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BriaCell Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
59th Percentile Overall Score

BCTX MarketRank™: 

BriaCell Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 475th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BriaCell Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about BriaCell Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for BriaCell Therapeutics are expected to grow in the coming year, from ($0.58) to ($0.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BriaCell Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BriaCell Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BriaCell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.30% of the float of BriaCell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BriaCell Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BriaCell Therapeutics has recently increased by 61.98%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BriaCell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    BriaCell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.30% of the float of BriaCell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BriaCell Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BriaCell Therapeutics has recently increased by 61.98%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BriaCell Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    Only 4 people have searched for BCTX on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.77% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.42% of the stock of BriaCell Therapeutics is held by institutions.

  • Read more about BriaCell Therapeutics' insider trading history.
Receive BCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCTX Stock News Headlines

Urgent: This election is rigged
If you missed it, my emergency election broadcast is now available - but will be removed soon
BriaCell Therapeutics Announces $5 Million Offering
See More Headlines

BCTX Stock Analysis - Frequently Asked Questions

BriaCell Therapeutics' stock was trading at $5.85 at the beginning of the year. Since then, BCTX stock has decreased by 86.4% and is now trading at $0.7945.
View the best growth stocks for 2024 here
.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) posted its earnings results on Monday, October, 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.45.

BriaCell Therapeutics (BCTX) raised $15 million in an initial public offering (IPO) on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

BriaCell Therapeutics' top institutional investors include Vontobel Holding Ltd. (0.44%).
View institutional ownership trends
.

Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Plug Power (PLUG), Micron Technology (MU) and Permian Basin Royalty Trust (PBT).

Company Calendar

Last Earnings
10/28/2024
Today
11/02/2024
Next Earnings (Estimated)
12/12/2024
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BCTX
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+1,788.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.24) per share

Miscellaneous

Free Float
28,036,000
Market Cap
$28.47 million
Optionable
Optionable
Beta
1.34
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:BCTX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners